Eileen Holmes

+44 (0)1382 381365


Dr Eileen Holmes is a Statistician in the Dundee Epidemiology and Biostatistics Unit (DEBU), in the Division of Population Health Science within the School of Medicine, University of Dundee. She started in August 2017 in a new joint post between the university and the Scottish Medicines Consortium (SMC) under the supervision of Prof Peter Donnan. The SMC carries out early health technology assessment (HTA) of all new medicines and has a remit to provide advice to NHS Boards and their Area Drug and Therapeutic Committees (ADTCs) across Scotland. Her main role is to manage, deliver and further develop the provision of statistical advice to the SMC.

Prior to joining the team in DEBU, she has worked as a statistician in clinical trials (Frontier Science Scotland, 2010-2017), occupational health (Health and Safety Laboratory, 2008-2010) and public health (Salford Royal Hospital, 2003-2008; University of Strathclyde, 1998-2002).



A member of the New Drugs Committee of the Scottish Medicines Consortium that gives guidance on prescribing of new drugs for Scotland.


Note: some publications are in her maiden name, Wright.

Allardice, G.M., Wright, E.M., Peterson, M. and Miller, J.M. (2001) A statistical approach to an outbreak of endophthalmitis following cataract surgery at a hospital in the West of Scotland. Journal of Infection, 49, 1, 23-29.

Bowman, A.W. and Wright, E.M. (2000) Graphical exploration of covariate effects on survival data through nonparametric quantile curves, Biometrics, 56, 2, 563-570.

Campbell, H., Holmes, E., Macdonald, S., Morrison, D. and Jones, I. (2002) A capture-recapture model to estimate prevalence of children born in Scotland with developmental eye defects. Journal of Cancer Epidemiology and Prevention. 7(1):21-8.

Chitty, L.S., Chudleigh, P., Wright, E.M., Campbell, S and Pembrey, M. (1998) The significance of choroid plexus cysts in an unselected population: the results of a multicentre study. Ultrasound in Obstetrics and Gynecology, 12, 6, 391-397.

Cook, G.T., Scott, E.M., Wright, E.M., Anderson, R. (1992) The statistics of low-level counting using new generation Packard liquid scintillation counters. Radiocarbon, 34, 360-365.

de Azambuja, E., Holmes, A.P., Piccart-Gebhart, M., Holmes, E., Di Cosimo, S., Swaby, R.F., Untch, M., Jackish, C., Lang, I., Smith, I., Boyle, F., Xu, B., Barrios, C.H., Perez, E.A., Azim Jr, H.A., Kim, S-B., Kuemmel, S., Huang, C-S., Vuylsteke, P., Hsieh, R-K., Gorbunova, V., Eniu, A., Dreosti, L., Tavartkiladze, N., Gelber, R.D., Eidtmann, H., and Baselga, J. (2014) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. (2014) Lancet Oncology, 15 (10), 1137-1146. http://dx.doi.org/10.1016/S1470-2045(14)70320-1

Gebhart, G., Gámez, C., Holmes, E., Robles, J., Garcia, C., Cortés, M., de Azambuja, M.E., Fauria, K., Van Dooren, V., Aktan, G., Coccia-Portugal, M., Kim, S., Vuylsteke, P., Cure, H., Eidtmann, H., Baselga, J., Piccart, M., Flamen, P. and Di Cosimo, S. (2013) FDG-PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. Journal of Nuclear Medicine, published online on October 3, 2013 as doi:10.2967/jnumed.112.119271

Gingras, I., Holmes, E., de Azambuja, E., Nguyen, D.H.A., Izquierdo, M., Zujewski, J.A., Inbar, M., Naume, B., Tomasello, G., Gralow, J.R., Wolff, A.C., Harris, L., Gnant, M., Moreno-Aspitia, A., Piccart, M.j., Azim, H.A. Jr. (2017) Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial. Journal of the National Cancer Institute, (2017) 109 (8): djw331. https://doi.org/10.1093/jnci/djw331

Holmes, E. (2013) The Pesticide Users’ Health Study: Survey of pesticide usage. Health and Safety Executive Research Report 957. http://www.hse.gov.uk/research/rrpdf/rr957.pdf

Holmes, E. (2009) Review of sickness absence in the waste and recycling industry. Health and Safety Executive Research Report 750. http://www.hse.gov.uk/research/rrpdf/rr750.pdf

Holmes, E. (2008) The feasibility of comparing sickness absence surveys and the Labour Force Survey. Health and Safety Executive Research Report 673. http://www.hse.gov.uk/research/rrpdf/rr673.pdf

Holmes, E.M. and Chadwick, P.C. (2006) Monitoring MRSA in an acute NHS trust. Journal of Hospital Infection. 63, Issue 1, Pages 109–111

Krick, J., Murphy-Miller, P., Zeger, S., Wright, E. (1996) Pattern of growth in children with cerebral palsy. Journal of the American Dietetic Association, 96, 680-685.

Kyaw, M.H., Holmes, E.M., Chalmers, J., Jones, I.G. and Campbell, H. (2002) A survey of vaccine coverage and antibiotic prophylaxis in splenectomised patients in Scotland. Journal of Clinical Pathology, 55, 472-474.

Kyaw, M.H., Wayne, B., Holmes, E.M., Jones, I.G. and Campbell, H. (2002) Influenza and pneumococcal vaccination in Scottish nursing homes: coverage, policies and reasons for receipt and non-receipt of vaccine. Vaccine, 20, 2516-2522.

Kyaw, M.H., Holmes, E.M., Toolis, F., Wayne, B., Chalmers, J., Jones, I.G. and Campbell, H. (2006) Evaluation of severe infection and survival after splenectomy. American Journal of Medicine, 119, 276.e1-276.e7.

Locking, M.E., O'Brien, S.J., O'Reilly, W.J., Wright, E.M., Campbell, D.M., Coia, J.E., Browning, L.M. and Ramsay, C.N. (2001) Risk factors for sporadic cases of Escherichia coliO157 infection: the importance of contact with animal excreta. Epidemiology and Infection, 127, 215-220.

Loibl, S., Majewski, I., Guarneri, V., Nekljudova, V., Holmes, E., Bria E., Denkert, C., Schem, C., Sotiriou, C., Loi, S., Untch, M., Conte, P., Bernards, R., Piccart, M., von Minckwitz, G., Baselga, J. (2016) PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer – pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Annals of Oncology, doi:10.1093/annonc/mdw197

Kurmanavicius J., Wright E.M., Royston P., Wisser J., Huch R., Huch A., Zimmermann R. (1999) Fetal ultrasound biometry: 1. Head reference values.British Journal of Obstetrics and Gynaecology,106(2):126-35.

Kurmanavicius J., Wright E.M., Royston P., Zimmermann R., Huch R., Huch A., Wisser J. (1999) Fetal ultrasound biometry: 2. Abdomen and femur length reference values.British Journal of Obstetrics and Gynaecology,106(2):136-43.

Majewski, I.J., Nuciforo, P., Mittempergher, L., Bosma, A.J., Eidtmann, H., Holmes, E., Sotiriou, C., Fumagalli, D., Jimenez, J., Aura, C., Prudkin, L., Díaz-Delgado, M.C., de la Peña, L., Loi, S., Ellis, C., Schultz, N.,, de Azambuja, E., Harbeck, N., Piccart-Gebhart, M., Bernards, R., Baselga, J. (2015) PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer, Journal of Clinical Oncology, Apr 20, 1334-1339.

McCabe, G., Greenhalgh, D., Gettinby, G. Holmes, E. and Cowden, J. (2003) Prediction of infectious diseases: an exception reporting system. Journal of Medical Informatics and Technologies, 5, MI-67 – MI-74.

Nuciforo, P.G., Aura C., Holmes E., Prudkin L., Jimenez J., Martinez P., Ameels, H., de la Peña L., Ellis, C., Eidtmann, H., Piccart-Gebhart, M.J., Scaltriti, M., Baselga, J. (2015) Benefit to neoadjuvant anti–Human Epidermal Growth Factor Receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of Phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. Annals of Oncology, 26 (7) 1494-1500.

Ogueh, O, Wright, E.M., Jones, J., Alaghband-Zadeh, J., Nicolaides, K.H. and Johnson, M.R. (2001) Fetal bone metabolism in normal and rhesus isoimmunised pregnancies. British Journal of Obstetrics and Gynaecology, 108, 9, 986-992.

Omar, R.Z., Wright, E.M., Turner, R.M. and Thompson, S.G. (1999) Analysing repeated measurements data: A practical comparison of methods, Statistics in Medicine, 18, 1587-1603.

O’Sullivan, C.C., Bradbury, I., Campbell, C., Spielmann, M., Perez, E.A., Joensuu, H., Costantino, J.P., Delaloge, S., Rastogi, P., Zardavas, D., Ballman, K.V., Holmes, E., de Azambuja, E., Piccart-Gebhart, M., Zujewski, J.A., and Gelber, R.D. (2015) Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer and Tumors 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. Journal of Clinical Oncology, 33 (24) 2600-2608.

Partridge, A.H., Gelber, S., Piccart-Gebhart, M.J., Focant, F., Scullion, M., Holmes, E., Winer, E.P., Gelber, R.D. (2013) Effect of age on breast cancer outcomes in women with HER-2 positive breast cancer: Results from a Herception Adjuvant Trial. Journal of Clinical Oncology, 31, 2692-2698.

Pestalozzi, B.C., Holmes, E., de Azambuja, E., Metzger-Filho, O., Hogge, L., Scullion, M., Lang, I., Wardley, A., Lichinitser, M., Lopez Sanchez, R.I., Muller, V., Dodwell, D., Gelber, R.D., Piccart-Gebhart, M.J., Cameron, D. (2013) CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncology, 14, 244-248.

Piccart-Gebhart, M., Holmes, E., Baselga, J., de Azambuja, E., Dueck, A.C., Viale, G., Zujewski, J.A., Goldhirsch, A., Armour, A., Pritchard, K.I., McCullough, A.E., Dolci, S., McFadden, E., Holmes, A.P., Tonghua, L., Eidtmann, H., Dinh, P., Di Cosimo, S., Harbeck, N., Tjulandin, S., Im, Y-H, Huang, C-S, Dieras, V., Hillman, D.W., Wolff, A.C., Jackisch, C., Lang, I., Untch, M., Smith, I., Boyle, F., Xu, B., Gomez, H., Suter, T., Gelber, R.D., and Perez, E.A. (2016) Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results from the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. Journal of Clinical Oncology, 34 (10) 1034-1042.

Royston, P. and Wright, E.M. (1998) A method for estimating age-specific reference intervals (`normal ranges') based on fractional polynomials and exponential transformation. Journal of the Royal Statistical Society, Series A., 161, 79-101.

Royston, P. and Wright, E.M. (1998) How to construct ‘normal ranges’ for fetal variables. Ultrasound Obstetrics and Gynecology, 11, 30-38.

Royston, P. and Wright, E.M. (2000) Goodness-of-fit statistics for age-specific reference intervals. Statistics in Medicine, 19, 21, 2943-2962.

Shi, W., Jiang, T., Nuciforo, P., Hatzis, C., Holmes, E., Harbeck, N., Sotiriou, C., Peña, L., Loi, S., Rosa, D.D., Chia, S., Wardley, A., Ueno, T., Rossari, J., Eidtmann. H., Armour, A., Piccart-Gebhart, M., Rimm, D.L., Baselga, J., Pusztai, L. (2017) Pathway level alterations rather than mutations in single genes predict response to HER2 targeted therapies in the neo-ALTTO trial. Annals of Oncology, 28 (1) 128-135.

Wright, E.M. and Royston, P. (1997) A comparison of statistical methods for age-related reference intervals. Journal of the Royal Statistical Society, Series A, 160, 47-69.

Wright, E.M. and Royston, P. (1997) Simplified estimation of age-specific reference intervals for skewed data. Statistics in Medicine, 16, 2785-2803.

Wright, E.M. and Royston, P. (1999) Calculating reference intervals for laboratory measurements. Statistical Methods in Medical Research, 8, 2, 93-112.

Wright, E.M. (1995) Nonparametric methods for the exploration and analysis of survival data. PhD thesis.